2023
- BLOG: Disability Tips
- HDSA Earns Four-Star Rating From Charity Navigator
- BLOG: This Week in HD Research
- Postcard from Dubrovnik: Highlights from the 2023 CHDI HD Therapeutics Conference
- uniQure Community Letter: Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy
- uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- Huntington’s Disease Society of America Awards 2023 Berman-Topper Family HD Career Development Fellowship
- HDSA Partnership with Rare-X Community Letter & FAQ
- HDSA and RARE-X Launch HD Data Collection Initiative to Accelerate Treatments for Huntington’s disease
- Now Available in the U.S.: Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets
- HDSA Awards Four 2023 Donald A. King Summer Research Fellowships
- HDBUZZ: PROOF-HD study of pridopidine ends with negative result
- Prilenia Announces Important Update About The Topline Results From Phase 3 Study, PROOF-HD.
- The HDSA Podcast Episode #3
- Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
- HDBuzz: Roche Phase II GENERATION HD2 study underway
- Huntington’s Disease Society of America Awards More Than $2 Million To Expand HDSA Centers of Excellence Network to Sixty-Seven Sites Across the US
- Louise Vetter provides statement in support of the FDA Listening Session on Juvenile Onset Huntington’s Disease
- HDSA Publishes 2022 Year in Review Magazine
- Introducing The HDSA Podcast
- Roche-Genentech Community Letter: GENERATION HD2 study now open
- 38th Annual HDSA Convention in New Orleans Registration Now Open
